










































MicroRNA-532-5p Regulates Pericyte Function by Targeting the
Transcription Regulator BACH1 and Angiopoietin-1
Citation for published version:
Slater, SC, Jover, E, Martello, A, Miti, T, Rodriguez-arabaolaza, I, Vono, R, Alvino, VV, Satchell, SC,
Spinetti, G, Caporali, A & Madeddu, P 2018, 'MicroRNA-532-5p Regulates Pericyte Function by Targeting
the Transcription Regulator BACH1 and Angiopoietin-1' Molecular Therapy. DOI:
10.1016/j.ymthe.2018.08.020
Digital Object Identifier (DOI):
10.1016/j.ymthe.2018.08.020
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Please cite this article in press as: Slater et al., MicroRNA-532-5p Regulates Pericyte Function by Targeting the Transcription Regulator BACH1 and
Angiopoietin-1, Molecular Therapy (2018), https://doi.org/10.1016/j.ymthe.2018.08.020Original ArticleMicroRNA-532-5p Regulates Pericyte Function
by Targeting the Transcription Regulator
BACH1 and Angiopoietin-1
Sadie C. Slater,1 Eva Jover,1 Andrea Martello,2 Tijana Mitic,2 Iker Rodriguez-Arabaolaza,1 Rosa Vono,3
Valeria V. Alvino,1 Simon C. Satchell,4 Gaia Spinetti,3 Andrea Caporali,2 and Paolo Madeddu1
1Bristol Heart Institute, Translational Health Sciences, University of Bristol, Bristol Royal Inﬁrmary, Bristol BS2 8HW, UK; 2University/BHF Centre for Cardiovascular
Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK; 3Laboratory of Cardiovascular Research, IRCCS MultiMedica, Milan
20138, Italy; 4Bristol Renal, Translational Health Sciences, University of Bristol, Whitson Street, Bristol BS1 3NY, UKMicroRNAs regulate endothelial function and angiogenesis,
but their implication in pericyte biology remains undeter-
mined. A PCR array, covering a panel of 379 human
microRNAs, showed microRNA-532-5p to be one of the most
differentially modulated by hypoxia, which was conﬁrmed
by qPCR in both skeletal muscle and adventitial pericytes.
Furthermore, microRNA-532-5p was upregulated in murine
muscular pericytes early after experimentally induced ischemia,
decreasing below baseline after reperfusion. Transfection of
human pericytes with anti-microRNA, microRNA-mimic, or
controls indicates microRNA-532-5p modulates pro-angio-
genic activity via transcriptional regulation of angiopoietin-1.
Tie-2 blockade abrogated the ability of microRNA-532-5p-
overexpressing pericytes to promote endothelial network for-
mation in vitro. However, angiopoietin-1 is not a direct target
of microRNA-532-5p. In silico analysis of microRNA-532-5p
inhibitory targets associated with angiopoietin-1 transcription
indicated three potential candidates, BACH1, HIF1AN, and
EGLN1. Binding of microRNA-532-5p to the BACH1 30 UTR
was conﬁrmed by luciferase assay. MicroRNA-532-5p silencing
increased BACH1, while a microRNA-532-5p mimic decreased
expression. Silencing of BACH1 modulated angiopoietin-1
gene and protein expression. ChIP conﬁrmed BACH1 tran-
scriptional regulation of angiopoietin-1 promoter. Finally,
microRNA-532-5p overexpression increased pericyte coverage
in an in vivoMatrigel assay, suggesting its role in vascularmatu-
ration. This study provides a newmechanistic understanding of
the transcriptional program orchestrating angiopoietin-1/Tie-2
signaling in human pericytes.Received 12 March 2018; accepted 23 August 2018;
https://doi.org/10.1016/j.ymthe.2018.08.020.
Correspondence: Paolo Madeddu, MD, FAHA, Chair of Experimental Cardio-
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Angiogenesis is a tightly regulated process that involves the interac-
tion between endothelial cells (ECs) and pericytes (PCs).1 Current
mechanistic understanding indicates the canonical angiopoietin
(Ang)/Tie-2 pathway plays a key role in the paracrine cross-talk be-
tween the two cell populations.2–4 Tie-2 expressed by ECs is activated
by PC-secreted Ang-1, resulting in the induction of downstreamMolec
This is an open access article undepathways mediating survival, proliferation, migration, and anti-in-
ﬂammatory signals. In contrast, Ang-2 acts as a partial agonist of
Tie-2, inhibiting Tie-2 signaling in the presence of Ang-1, but acti-
vating Tie-2 in the absence of Ang-1.5 Surprisingly, little is known
about the transcriptional regulation of the Ang/Tie-2 pathway.
MicroRNAs (miRs) are small noncoding RNAs that function in
diverse biological processes via post-transcriptional gene regulation.
They modulate protein expression by binding to complementary or
partially complementary target sites in the 30 UTRs of mRNA, causing
inhibition of gene expression.6 miRs have been identiﬁed in cells,6
serum, and plasma.7 Some miRs remain within the cell-modifying
transcriptional regulation, while others are released, acting like para-
crine or endocrine factors.8,9 Changes in the expression proﬁle of
several miRs have been associated with cardiovascular processes
and diseases.10,11 In particular, a class of miRs is speciﬁcally modu-
lated by hypoxia and implicated in the regulation of angiogenesis.
These hypoxia-miRs are in the focus of intense research and represent
potential targets for the treatment of ischemic disease.12 Nevertheless,
a few studies have addressed the participation of miRs in the regula-
tion of PC functions.13–16 Moreover, although some data exist on the
hypoxia-induced Let-7d having a role in PC differentiation,17 no sys-
tematic analysis has been carried out to characterize the proﬁle of
hypoxia-miRs that target angiogenic genes in human PCs.
The present study investigates the effect of hypoxia on global miR
expression in a subset of human CD34+ and CD146 PCs isolated
from the saphenous vein—adventitial PCs (APCs). Within the
miRs identiﬁed to be differentially modulated by hypoxia, we focused
onmiR-532-5p because, while being reportedly expressed in cancer,18
rheumatoid arthritis,19 epilepsy,20 and deep vein thrombosis,21 itsular Therapy Vol. 26 No 12 December 2018 ª 2018 The Authors. 1
r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Individual Results for the Top 19 Most Differentially Expressed
miRs
miR Name SD Fold Change (2Dct) p Value
hsa-miR-210 1.5 3.2 0.0072
hsa-miR-98-5p 0.14 1.3 0.010
hsa-miR-192-5p 0.51 2.5 0.014
hsa-let-7f-5p 0.13 1.2 0.017
hsa-miR-532-5p 0.16 1.3 0.021
hsa-miR-99b-5p 0.12 1.2 0.024
hsa-let-7d-5p 0.13 1.2 0.027
hsa-miR-18a-5p 0.090 1.1 0.028
hsa-miR-432-5p 0.11 1.2 0.030
hsa-miR-539-5p 0.23 1.4 0.030
hsa-miR-16-5p 0.066 1.1 0.030
hsa-miR-299-3p 0.55 2.1 0.030
hsa-miR-149-5p 0.35 1.6 0.031
hsa-miR-196b-5p 0.085 1.1 0.031
hsa-miR-128 0.19 1.3 0.033
hsa-miR-654-5p 0.40 1.7 0.033
hsa-miR-339-5p 0.27 1.4 0.042
hsa-miR-423-5p 0.26 1.3 0.047
hsa-miR-30c-2-3p 0.44 2.3 0.049
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study showed miR-532-5p exerts a protective action in a model of
myocardial infarction by repressing maladaptive transition of
coronary ECs to a ﬁbroblast-like phenotype via endothelial-to-
mesenchymal transition.22 Results here show for the ﬁrst time a
new molecular mechanism centered on miR-532-5p, which by inhib-
iting the transcriptional repressor BTB and CNC homology 1
(BACH1) induces the expression and secretion of Ang-1 by human
PCs. Activation of this signaling mechanism results in autocrine inhi-
bition of PC apoptosis and paracrine activation of EC migration and
angiogenic activity.
RESULTS
Characterization of Cell Phenotype
PCs are classically identiﬁed as mural cells surrounding capillaries
and arterioles in tissues and vasa vasorum in the adventitia of
large vessels. Both populations express PDGFR-b, CSPG4 (NG2),
ACTA2 (SMA), Desmin, T-box family transcription factor (Tbx18),
and CD248 but differ with regard to CD146, which is acknowledged
as a distinctive marker for muscle PCs (MCPs).2,23,24 Here, we
conﬁrmed the typical phenotype of expanded human PCs by ﬂow cy-
tometry and immunocytochemistry. Saphenous vein-derived APCs
express PDGFR-b, CD90, CD73, CD105, and CD44 but are negative
for CD34, CD31 (PECAM-1), CD146, and CD45 (Figure S1A).
Furthermore, APCs stain positive for PDGFR-b, GATA-4, and vi-
mentin, but do not express VE-cadherin (Figure S1B). The typical
proﬁle of PCs from human skeletal muscles (MPCs) was veriﬁed by2 Molecular Therapy Vol. 26 No 12 December 2018immunocytochemistry for NG2, PDGFR-b, CD146, and CD56 and
ﬂow cytometry identiﬁcation of alkaline phosphatase (ALP). Addi-
tionally, MPCs were negative for the endothelial antigen CD31 and
the satellite cell marker PAX7 (Figure S1C).
Effect of Hypoxia on miR Profile in Human APCs
We ﬁrst used a PCR array, covering a panel of 379 most common hu-
manmiRs, to assess the change in the APCmiR proﬁle from normoxia
to hypoxia (48 hr, 2% O2). Controls (“no template” sample in the
reverse transcription step [negative control] and RNA spike-in [tech-
nical control]) indicated good performance of the proﬁling experi-
ment. Four APC cell lines, each derived from individual patient saphe-
nous vein samples, were tested. The array detected 175 miRs, in all
studied cell lines, with an average of 209 being detected per sample
(data not shown). When comparing normoxic to hypoxic samples
using a paired t test, 19 miRs were found to be differentially expressed
using a cutoff p value < 0.05 (Table 1). Due to the small number of
patient samples used for the array, no multiple comparison correction
was applied. Of the 19miRs, 4 were upregulated and 15 downregulated
in response to the hypoxic stimulus. The ﬁrst four top hits in the list
(miR-210, miR-98-5p, miR-192-5p, and let-7f-5p) have been previ-
ously associated with angiogenesis.25–28 Interestingly, however, we
could not ﬁnd any published data about an association of miR-532-
5p, the ﬁfth top hit, with human PCs, hypoxia, or angiogenesis.
Validation of the miR array by qPCR conﬁrmed miR-532-5p down-
regulation in APCs (passage 7) exposed to hypoxia for 48 hr (29%,
p < 0.001 versus normoxia; Figure 1A), this effect persisting after re-
turn of cells from hypoxia to normoxia for 48 hr (p < 0.05 versus basal
normoxia or hypoxia; Figure 1B). We also found the depressant effect
of hypoxia is reproduced at early stage of APC expansion (passage 3;
data not shown).
Changes in the degree of mutual cell contacts, such as following PC
detachment from neighboring ECs at the initial stage of angiogenesis
or in vitro culture at different cell densities, reportedly affect the gene
expression and expansion capacity.29,30 Consistently, we found that
cell density signiﬁcantly affects the miR-532-5p expression of human
APCs (Figure 1B). Overall, these data indicate intracellular miR-532-
5p levels are differentially modulated by changes in the culture
microenvironment.
Effect of Hypoxia and Ischemia on miR-532-5p in Human MPCs
We next investigated if hypoxia modulates miR-532-5p in PCs
derived from another anatomical source, skeletal muscles. Results
conﬁrm hypoxia reduces the levels of miR-532-5p in human MPCs
(Figure 2A). Next, we asked if miR-532-5p expressional changes
following in vitro hypoxia are reproduced in MPCs freshly harvested
from ischemic muscles. To this aim, we compared the miR levels in
MPCs isolated from muscular biopsies of healthy subjects (CONTR)
or critical limb ischemia (CLI) patients with or without concomitant
type 2 diabetes mellitus (T2D) a condition known to jeopardize
vascular repair and PC functions (Figure 2B).31–34 Intriguingly, we
found that miR-532-5p levels are markedly higher in MPCs from
Figure 1. Effect of Hypoxia on miR Profile in Human
APCs
(A) Validation of miR532-5p expression by qPCR confirms
reduction of intracellular levels following APCs’ exposure to
48 hr hypoxia (i, n = 6 biological replicates) or 48 hr hypoxia
followed by return to 48 hr normoxia (ii, n = 4 biological
replicates). *p < 0.05 and ***p < 0.001 versus normoxia. (B)
MiR-532-5p expression is also affected by cell density
(n = 4 biological replicates). *p < 0.05 versus confluent
APCs. Values are means ± SE.
www.moleculartherapy.org
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being abolished by coexisting T2D (p = N.S. versus CONTR; p <
0.05 versus CLI).
We veriﬁed the upregulation of miR-532-5p by ischemia by assessing
the miR levels in immunosorted NG2+ MPCs from our recent study
in a murine model of unilateral limb ischemia.15 Results conﬁrmed
the remarkable upregulation of miR-532-5p in MPCs from ischemic
muscles of otherwise healthy mice (Figure 3A). The levels of miR-
532-5p peaked at day 3 post-ischemia (2.5-fold, p < 0.0001 versus
time 0) and then decreased to below the baseline values by day 15
post-ischemia (p < 0.01 versus time 0). Interestingly, the time-based
changes in miR-532-5p were contrary to the Doppler blood ﬂow
changes (expressed as ischemic to contralateral blood ﬂow ratio),
thus indicating an inverse relationship between the two measure-
ments (Figure 3A). Furthermore, we compared the levels of miR-
532-5p in NG2+ MPCs sorted from ischemic and contralateral limb
muscles of healthy and streptozotocin (STZ)-induced type 1 diabetic
(T1D) mice. Results indicate the inductive effect of ischemia on miR-
532-5p was completely abrogated by the concomitance of diabetes
(Figure 3Bi). This inhibitory effect of T1D on miR-532-5p was paral-
leled by a worse perfusion recovery, as assessed by calculating the area
under the curve of laser Doppler blood ﬂow measurements over
15 days post-ischemia (Figure 3Bi) and by a reduced microvascularMolecapillary density (Figures 3Bii and 3Biii), as
assessed by immunohistochemistry (653 ± 25
versus 960 ± 30 capillaries/mm2 in healthy
mice, p < 0.001).
Autocrine and Paracrine Effects of miR-532-
5p Modulation in Human APCs
Having demonstrated ischemia is a strong acti-
vator of miR-532-5p expression, we performed
in vitro assays to determine the effects of miR-
532-5p titration on APC-related functions.
Silencing and overexpression were achieved by
transfecting human APCs with miRVana anti-
miR inhibitor and miR mimic, respectively.
Anti-miR and miR-mimic negative controls
were used to exclude any unspeciﬁc effect of
transfection on observed functional responses.
Effective inhibition and overexpression of intra-cellular miR-532-5p were conﬁrmed by qPCR (Figures 4Ai and
4Aii). We could not ﬁnd miR-532-5p in APC conditioned media
except when the cells were transfected with the miR-mimic
(Figure 4Aiii).
We next explored if the titration of miR-532-5p causes autocrine ef-
fects in human APCs. Inhibition of miR-532-5p had no effect on APC
viability, metabolic activity, proliferation, apoptosis, or migration
(Figure 4B), whereas overexpression decreased both metabolic activ-
ity and apoptosis (p < 0.05 versus scrambled, for both comparisons)
but had no effect on viability, proliferation, or migration (Figure 4C).
We next investigated if forced changes inmiR-532-5p expression alter
the interaction between APCs and ECs. Interestingly, miR-532-5p in-
hibition abrogated the APC-induced stimulation of human umbilical
vein endothelial cells (HUVECs) network formation on Matrigel, as
assessed by measuring the cumulative branch length (p < 0.01 versus
scrambled; Figures 4Di and 4Dii). The opposite effect was seen in
response to miR-532-5p overexpression, which resulted in potentia-
tion of the stimulatory effect of APCs on network formation (p <
0.01 versus HUVECs alone and p < 0.05 versus HUVECs + Scram-
bled-transfected APCs; Figures 4Ei and 4Eii). However, no change
was observed in the number of APCs sitting on branches or nodes
(data not shown). Furthermore, miR-532-5p inhibition decreasedcular Therapy Vol. 26 No 12 December 2018 3
Figure 2. miR-532-5p Levels in Human MPCs
(A) Effect of 48 hr normoxia or hypoxia (2%O2) onmiR-532-
5p levels in human MPCs (n = 4 biological replicates). (B)
Levels of miR-532-5p in MPCs harvested from healthy
(CONTR) or ischemic muscles (CLI) with or without super-
imposed diabetes (T2D) (n = 5, 3, and 5, respectively). *p <
0.05 versus CONTR, ++p < 0.01 versus CLI. Values are
means ± SE.
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while overexpression of miR-532-5p increased resistance (p < 0.05
versus scrambled; Figure 4Fii).
mir-532-5p Modulates Ang-1 Expression in Human APCs
Considering miR-532-5p inﬂuences the control of network forma-
tion by APCs, we explored the possible participation of Ang-1 and
vascular endothelial growth factor A (VEGF-A), which are key
angiogenic factors produced by PCs,2 in these phenomena. Results
indicate the Ang-1/Tie-2 axis is indeed involved in the miR-532-
5p-induced promotion of in vitro angiogenesis. This is supported
by several pieces of evidence. First, miR-532-5p inhibition reduced
and miR-532-5p overexpression increased ANG-1 mRNA and
Ang-1 protein levels in human APCs (p < 0.05 to p < 0.01 versus
scrambled; Figures 5A and 5B), whereas no changes were seen in
VEGF-A expression (Figure S2). Second, a Tie-2 inhibitor was able
to block the promotion of HUVECs network formation by the
conditioned media of miR-532-5p-overexpressing APCs (Figure 5C).
On the other hand, inhibition of Tie-2 in miR-532-5p-overexpress-
ing APCs had no effect on apoptosis when measured by caspase
assay (data not shown), thus discounting an effect of Ang-1 on
the promotion of APC viability by miR-532-5p.
miR-532-5p Regulates Ang-1 via Inhibition of the Transcription
Factor BACH1
miRTarBase predicted RUNX3, TRAPPC2P1,METTL20, ZFHX3, and
CPNE1 to be direct targets of miR-532-5p. However, we did not ﬁnd
any change in the expression of the above genes when miR-532-5p
expression was inhibited (Figure S3). Western blots to examine pro-
tein expression for each gene of interest also showed no regulation
(data not shown).
As miR-532-5p is not predicted to target ANG-1 directly, we per-
formed an in silico analysis for gene targets of miR-532-5p that could
regulate ANG-1. This resulted in three potential candidates, BACH1,
HIF1AN, and EGLN1. Modulation of miR-532 by anti-miR or mimic
did not affect the expression of eitherHIF1AN or EGLN1 (Figure S4).
In contrast, several lines of evidence identify the transcription factor
BACH1 as the key link between miR-532-5p and the Ang-1/Tie-2
signaling pathway. BACH1 (also known as BACH1, basic leucine4 Molecular Therapy Vol. 26 No 12 December 2018zipper transcription factor 1) reportedly acts
as a hypoxia-inducible repressor of gene expres-
sion and regulates important biological pro-
cesses including oxidative stress, inﬂammation,apoptosis, cell proliferation, ﬁbrosis, and angiogenesis.35 Importantly,
qPCR analysis demonstrated that when miR-532-5p was inhibited in
human APCs, BACH1 expression increased (Figure 6Ai). In contrast,
when miR-532-5p was overexpressed BACH1 expression decreased
(Figure 6Aii). Concomitant regulation of BACH1 protein expression
was conﬁrmed by western blotting (Figures 6Aiii and 6Aiv). The
TargetScan 6.2 algorithm predicted BACH1 contains a single
conserved binding sequence for miR-532-5p in its 30 UTR.36 To
conﬁrm that miR-532-5p directly binds the 30 UTR of BACH1, we
performed a reporter assay in which the luciferase reporter gene
was fused to the wild-type 30 UTR of BACH1. Overexpression of
miR-532-5p decreased luciferase activity for the putative target
gene, whereas mutation of the putative miR-532-5p binding site
within BACH1 prevented the miR-532-5p-induced reduction in lucif-
erase activity (Figure 6Av). Having demonstrated that BACH1 is un-
der the direct inhibitory control of miR-532-5p, we next asked the
question of whether BACH1 modulation could affect the expression
of ANG-1 in human APCs. Small interfering RNA (siRNA) was
used to silence BACH1 expression, which was conﬁrmed by qPCR
and western blot (Figure 6Bi and 6Bii). This resulted in an increase
in ANG-1 RNA levels in APCs (Figure 6Biii) and Ang-1 protein levels
in the APC-conditioned media (Figure 6Biv). Furthermore, we inves-
tigated the effect of BACH1 silencing on APC network formation
when in co-culture with HUVECs (Figure 6C). BACH1 silencing re-
sulted in an increase of cumulative branch length. To assess if ANG-1
is a direct target of BACH1-mediated transcriptional regulation,
chromatin immunoprecipitation (ChIP) assay coupled with qPCR
was performed. (Figure 6D). Utilizing the ENCODE database,37 the
BACH1 reads distribution from the ChIP-seq NCBI GEO:
GSM935580 ﬁle was visualized across the human genome in IGV
Browser (IGV_2.4.4).38,39 The BACH1 reads were assessed at the pro-
moter region of ANGPT1. We visualized one signiﬁcant peak in
chr8:108,507,212–108,509,973 corresponding to active promoter re-
gion1 on ANG-1, and a smaller peak in the region2 upstream
(chr8:108,499,983–108,505,507) (Figure 6Di). Genomic sequences
for both above binding regions were retrieved from UCSC, and
primers were designed. qPCR was performed with the precipitated
DNA and validated primers. Binding was detected in both regions
with much stronger ChIP-qPCR signal observed in region 1
(Figure 6Dii).
Figure 3. miR-532-5p Levels in Murine MPCs
(A) Bar graph showing the time course of miR-532-5p expression inmurine NG2+MPCs freshly sorted frommuscles of mice subjected to unilateral limb ischemia. The red line
graph illustrates the corresponding time course of laser Doppler blood flow measurements, which shows a trend opposite to that of miR-532-5p (n = 4 biological replicates,
**p < 0.01 and ***p < 0.001 versus time 0). (B) (i) Bar graph showing the miR-532-5p expression levels in NG2+ MCPs freshly sorted from ischemic and contralateral muscles
of healthy or streptozotocin-induced type 1 diabetic mice (STZ-T1D) at 3 days from induction of limb ischemia. The red circles represent the area under the curve of laser
Doppler blood flow measurements expressed as arbitrary units (AU; n = 4 biological replicates, **p < 0.01 versus MPCs isolated from contralateral non-ischemic muscle). (ii)
Bar graph showing capillary density in contralateral muscle 15 days post-ischemia (n = 4, ***p < 0.001 versus control. Values are means ± SE. (iii) Representative images of
immunohistological analysis of capillary density. Green staining, isolectin B4; blue staining, DAPI. Scale bar, 50 mm.
www.moleculartherapy.org
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Finally, we determined if modulation of miR-532-5p expression
affects the ability of human APCs to participate in the formation of
vascular networks upon transplantation in vivo. Results show an in-
crease in vessel coverage by miR-532-5p-overexpressing APCs as
compared with control APCs, thus suggesting that miR promotes
microvascular maturation (Figure 7).
DISCUSSION
There is a substantial paucity of data regarding the expression and
pathophysiological role of miRs in human PCs. We previously
showed that miR-132 plays a role in the pro-angiogenic and anti-
ﬁbrotic activity of APCs in a murine model of myocardial infarction,
respectively, through inhibition of Ras-GTPase-activating protein
and methyl-CpG-binding protein 2.16 The hypoxia-miR Let-7d was
found upregulated in PC-derived neurospheres and proposed to be
involved in PC differentiation.17 In another study, Caporali et al.15 re-
ported the PC uptake of EC-produced miR-503, which, by reducingthe expression of EFNB2 and VEGF-A, resulted in an impaired PC
migration and proliferation. The present study is the ﬁrst to investi-
gate the global hypoxia-induced miR proﬁle of human PCs and to
identify a number of miRs that are differentially regulated by hypoxia.
Nineteen miRs were found to be differentially expressed in response
to hypoxia when analyzed using a paired t test. Benjamini-Hochberg
correction was also applied to the array data; however, none of the
miRs passed this test. This is not surprising, as the sample number
tested was small (n = 4), and we observed variation in the amount
of miR expression in the samples, though the data trends were similar.
The amount of variation between samples when using human sam-
ples is a common problem. We performed additional qPCR replicates
on a further six patient cell lines to validate the expression of four
miRs highlighted by the miRNA array (miR-532-5p discussed above
and miR-210, -299-3p, and -339-5p, data not shown). All qPCR re-
sults agreed with the initial array data, so we are convinced the results
gained from this array are robust. The ﬁrst four top hits in the list
(miR-210, miR-98-5p, miR-192-5p, and let-7f-5p) have beenMolecular Therapy Vol. 26 No 12 December 2018 5
Figure 4. Effect of Forced Modulation of miR-532-
5p Expression
(A) Confirmation of effective transfection by miR modu-
lators, with anti-miR causing miR inhibition (i) and miR
mimic causing increased miR expression intracellularly
and in conditioned medium (ii and iii); n = 8 biological
replicates. *p < 0.05, **p < 0.01, ****p < 0.0001 versus
scrambled. (B) Inhibition of miR-532-5p does not affect
APC functions. (C) Forced expression of miR-532-5p
induces a decrease in metabolic activity and apoptosis;
n = 6 biological replicates, *p < 0.05 versus scrambled.
(D and E) The effect of miR-532-5p modulation on
network formation was investigated in a Matrigel assay.
(D) (i) Co-culture of miR-532-5p-inhibited APCs with
HUVECs significantly decreased the ability of the latter to
form networks on Matrigel compared to scrambled-
treated APCs; n = 9 biological replicates, **p < 0.01
versus HUVECs alone, ++p < 0.01 versus scrambled-
APCs. (ii) DiL (red) staining of APCs shows miR-532-5p
inhibition resulted in no change in the number of APCs
found on the network branches or in the nodes (repre-
sentative images, magnification 10). (E) (i) Over-
expression of miR-532-5p produced a significant in-
crease in branch formation compared to control, but no
change in the number of cells on branches or nodes was
observed (ii), Representative images, magnification 10;
n = 8 biological replicates, *p < 0.05 and **p < 0.01
versus HUVECs, +p < 0.05 versus scrambled-APCs. (F)
(i) Inhibition of miR-532-5p decreased HUVEC mono-
layer resistance, while (ii) miR-mimic increased resis-
tance; n = 5–8 biological replicates. *p < 0.05 versus
scrambled. Values are means ± SE.
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Figure 5. The Ang-1-Tie-2 Axis Is Involved in the Proangiogenic Effect of miR-532-5p
(A) Effects of miR-532-5p inhibition on ANG-1 mRNA (i) and protein levels (ii) in human APCs. (B) Effects of miR-532-5p forced expression on ANG-1 mRNA (i) and protein
levels (ii); n = 6 biological replicates per group. *p < 0.05 and **p < 0.01 versus Scrambled. (C) (i) Bar graph showing the effect of Tie-2 inhibition on the inductive effect of miR-
532-5p-overexpressing APC conditioned media (CM) on HUVECs network formation. (ii) Representative Matrigel images, 10 magnification; n = 3 biological replicates per
group. *p < 0.01 versus Scrambled-transfected APC CM. Values are means ± SE.
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to PCs. Here, we focused on miR-532-5p, the ﬁfth top hit, because
this miR was not previously associated with PCs, hypoxia, or
angiogenesis.MiR-532-5p is an intronic miR located in chromosome X and prev-
alently expressed in brain, cerebellum, and testis. There is a scarce in-
formation on miR-532-5p functions and target genes, with seminal
studies showing modulation of miR-532-5p in diseases such asMolecular Therapy Vol. 26 No 12 December 2018 7
Figure 6. miR-532-5p Regulates ANG-1 via Inhibition
of the Transcription Factor BACH1
(A) qPCR (i and ii) and western blotting (iii and iv)
demonstrating the effect of miR-532-5p inhibition (i and iii)
(n = 4 biological replicates) and overexpression (ii and iv)
(n = 5 biological replicates) on BACH1 gene and protein
expression in APCs. *p < 0.05 and **p < 0.01 versus
scrambled. v, Luciferase activity at 48 hr post-co-trans-
fection of HEK293T cells with miR-532-5p mimics and the
following plasmids: pMIR reported (empty vector), 30 UTR-
BACH1, and 30 UTR-BACH1mut (with mutation of the
putative miRNA target site) (n = 5 replicates). ***p < 0.001
versus control, +p < 0.05 versus mimic 30 UTR BACH1. (B)
qPCR, n = 4 (i), and representative western blot image,
n = 3 (ii), demonstrating siRNA silenced bothBACH1 gene
(****p < 0.0001 versus control) and protein expression,
respectively. Silencing BACH1 resulted in an increase
ANG-1mRNA (n = 6) (iii) and Ang-1 protein (n = 5) (iv). *p <
0.05 and **p < 0.01 versus scrambled. (C) Inhibition of
BACH1 expression produced a significant increase in
network formation compared with control (i); representa-
tive images, red color: DiL staining of pericytes, magnifi-
cation 10. n = 7 biological replicates (ii), *p < 0.05 and
**p < 0.01 versus HUVECs, +p < 0.05 versus HUVECs +
Scr-APCs. All values are means ± SE. (D) (i) BACH1
transcription factor binding sites by ENCODE ChIP-seq
from NCBI GEO: GSM935580 were consulted and sub-
sequent ChIP-qPCR performed for BACH1 occupancy of
the ANGPT1 promoter regions (1) chr8:108,507,212–
108,509,973 and (2) chr8:108,499,983–108,505,507,
transcribed in [] direction. (ii) ChIP-qPCR analysis
confirms the regulation of ANG-1 by BACH1. qPCR
values are expressed as mean ± SE and are
representative of n = 3 independently performed qPCR
experiments with one biological replicate of APC. *p <
0.05 versus mIgG.
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Figure 7. In Vivo Matrigel Plug Assay Shows miR-532-p Expression Modifies the APC Ability to Stimulate Angiogenesis In Vivo
Control, miRNA mimic, or anti-miRNA treated pericytes (GFP-positive) plus HUVECs embedded into Matrigel were implanted subcutaneously into nude mice. (i) Confocal
analysis of representative cryostat sections of the Matrigel plug: PCs are stained with an anti-GFP antibody (green) and HUVECs with VE-cadherin antibody (red). Scale bars,
50 mm for large images and 25 mm for the inset; (5 5 tiled image). (ii) Results of quantification of areas of endothelium VE-cadherin positive (in percentage in onemicroscopic
view); (iii) ratio of the pericyte-covered endothelium (in percentage). Bars in the graphs represent mean values ± SE, (n = 5) *p < 0.05.
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Another report indicates porcine adipose tissue-derived mesen-
chymal stem cells secrete vesicle-packaged miR-532-5p.41 Further-
more, Bayoumi et al.22 recently reported that coronary ECs lacking
miR-532-5p exhibit increased transition to a ﬁbroblast-like pheno-
type via endothelial-to-mesenchymal transition, while ECs overex-
pressing miR-532-5p display decreased endothelial-to-mesenchymal
transition.22 Mechanistically, this effect was in part attributed to
direct repression of a positive regulator of maladaptive endothelial-
to-mesenchymal transition, prss23 (a protease serine 23).
The present study indicates miR-532-5p is regulated by hypoxia and
ischemia, though the two conditions exert opposite effects, with the
former inducing a modest but signiﬁcant downregulation, while the
latter causing a substantial increase in miR-532-5p. Hypoxia is just
one of the many factors that characterize the microenvironment of
an ischemic tissue. We tried to reproduce the ischemic condition
in vitro by exposing APCs to growth factors and chemokines, such
as VEGF-A, SDF-1, and interleukin-8 (IL-8), and stressors, such as
H2O2, without succeeding in inducing miR-532-5p expression
(P.M., unpublished data). Furthermore, we investigated miR-532-5p
expression in response to hypoxia over a range of time points (24,
48, 72, and 96 hr) to see if the miR-532-5p expression was induced.
However, no change was seen at 24 hr, while a signiﬁcant reduction
in expression was conﬁrmed at 24 hr and still observed after 72 and96 hr of hypoxia (P.M., unpublished data). A wider range of time
points at the early stages of hypoxia may be more informative. In
the in vivo limb ischemia model, we observed miR-532-5p expression
by skeletal MPCs to be initially increased at the peak of hypoperfusion
and then reduced during reperfusion, which may suggest an inﬂuence
of hemodynamic factors. This possibility is supported by the observa-
tion that diabetes, which delays the reperfusion of ischemic tissues,
antagonized the upregulation of miR-532-5p in human and murine
PCs. The identiﬁcation of miR-532-5p inducers requires further
investigation.
By using inhibitory or mimicry approaches, we showed miR-532-5p
exerts both autocrine and paracrine actions. On one hand, the miR
promotes pro-survival effects in PCs, and on the other hand, it sup-
ports EC network formation and increases vascular permeability.
Silencing of miR-532-5p did not alter the expression of predicted
target genes RUNX3, TRAPPC2P1, METTL20, ZFHX3, and CPNE1
or the prototypical angiogenic factor VEGF-A. Intriguingly, we
discovered that miR-532-5p modulates Ang-1 expression. Substantial
evidence indicates that the Ang/Tie system is essential for vessel re-
modeling and for the recruitment of mural cells and consequent
vessel maturation during embryonic development and adult vessel
homeostasis.42,43 Mechanistic studies suggest the participation of
Notch signaling through serine/threonine kinase (AKT)-mediated
activation of b-catenin.44 Preclinical trials using adenoviral-mediatedMolecular Therapy Vol. 26 No 12 December 2018 9
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potent Ang-1 variant, showed therapeutic acceleration of tissue heal-
ing through potentiation of angiogenesis and lymphangiogenesis.47
Intriguingly, despite the important role of Ang-1 in vascular biology,
little is known regarding its expressional regulation in human PCs. A
recent study showed that hypoxia induces Ang-1 expression in bovine
retinal PCs through transcriptional activation by the Hypoxia-induc-
ible factor-2a (HIF2a, also known as endothelial PAS domain protein
1 [EPAS1]).48 Therefore, we attempted to understand whether miR-
532-5p could be an Ang-1 inducer. To conﬁrm this possibility, we
titrated the expression of miR-532-5p and found that inhibition of
miR-532-5p decreases Ang-1 expression in APCs, while overexpres-
sion of miR-532-5p had the opposing effect. Furthermore, blocking
Ang-1 binding to the Tie-2 receptor on ECs resulted in a decrease
in network formation when HUVECs were cultured in conditioned
media from APCs overexpressing miR-532-5p. However, Ang-1 is
not a direct target for miR-532-5p. Using in silico analysis, we identi-
ﬁed BACH1 as a target of miR-532-5p that could also potentially
modulate Ang-1 expression.
BACH1 is reportedly expressed by ECs and plays an inhibitory activ-
ity on angiogenesis, though no link with Ang-1 has been reported.
In vitro, BACH1 overexpression suppresses EC proliferation and in-
duces cell-cycle arrest and apoptosis by increasing mitochondrial
ROS production.49 The best characterized molecular mechanism
downstream of BACH1 involves the transcriptional suppression of
heme oxygenase-1 (HO-1), a hypoxia-induced protein.50 In wild-
type mice with hindlimb ischemia, BACH1 forced expression impairs
reparative angiogenesis through inhibition of the Wnt/b-catenin
signaling pathway. In contrast, BACH1 knockout mice show an
enhanced angiogenic response to ischemia, which translates into
improved limb muscle reperfusion as compared to wild-type
controls.51
In our study, overexpression and inhibition of miR-532-5p were
shown to modulate the expression of BACH1 in APCs. The target-
ing of BACH1 by miR-532-5p was conﬁrmed using a luciferase re-
porter assay to prove the 30 UTR of BACH1 contains a binding site
miR-532-5p, further verifying the in silico results. As far as we are
aware, this is the ﬁrst demonstration of a role for miR-532-5p in
modulating BACH1 expression. To conﬁrm miR-532-5p inﬂuences
targets downstream of BACH1, we designed a target site blocker
oligonucleotide sequence complementary to the miR-532-5p bind-
ing site on the promoter region of BACH1. However, transfection
of this sequence into APCs was found to have toxic effects, even
at low dosage, a result we report for completeness of the informa-
tion (P.M., unpublished data). This side effect is a recognized prob-
lem with oligonucleotide sequences which contain a phosphoro-
thioate backbone.52
The alternative approach of silencing BACH1 conﬁrmed that the
transcription factor acts as a suppressor of Ang-1 expression in
APCs, so that when BACH1 is inhibited, ANG-1 is transcribed and
secreted, resulting in potentiation of in vitro EC network formation.10 Molecular Therapy Vol. 26 No 12 December 2018BACH1 transcriptional repression of ANG-1 was further conﬁrmed
using ChIP analysis, demonstrating that BACH1 occupies two bind-
ing regions on the promoter of ANG-1. Importantly, this translated
into potentiation of in vivo angiogenesis, where subcutaneous
implantation of miR-532-5p-overexpressing APCs caused an increase
in PC coverage of microvessels and greater expression of VE-cad-
herin, suggesting a role in microvessel maturation.
Conclusions
This is the ﬁrst study to show a regulatory pathway for the expression
of Ang-1 in PCs.We show compelling evidence for a novel angiogenic
mechanism that involves the induction of Ang-1 through miR-532-
5p-mediated inhibition of the transcriptional repressor BACH1, lead-
ing to modulation of network formation in models of angiogenesis.
miR-532-5p has been implicated in the modulation of epithelial-to-
mesenchymal transition. Our data indicate that miR could play a
role in the transition of PCs from a quiescent to an activated angio-
genic phenotype. These results provide important information in
the regulation of a key angiogenic pathway and reveal a previously
unknown associative role for miR-532-5p and BACH1 in vascular
biology, which may translate into new therapeutic avenues in repar-
ative and tumoral angiogenesis.
MATERIALS AND METHODS
Ethics of Human Studies
Studies using human cells were covered by Research Ethics Commit-
tee approvals (06/Q2001/197 and 11/2009) and complied with the
principles stated in the Declaration of Helsinki. All the subjects
gave informed written consent for the experimental use of donated
material. APCs were isolated from saphenous vein leftovers from cor-
onary artery graft bypass surgery. MPCs were isolated from biopsy
material obtained from different anatomic districts of the lower
extremities from subjects referred for investigations or therapeutic
interventions related to leg varicosity or suspected bone-related
pathologies that then resulted in negative (controls, n = 8) or from
sartorius muscles from patients at the occasion of major amputation
for CLI without (CLI, n = 3) or with (T2D + CLI, n = 5) superimposed
diabetes. CLI was diagnosed according to TASC 2007 i.e., rest pain
and/or ulcer or gangrene, transcutaneous oximetry at the dorsum
of the foot <30 mmHg and/or ankle pressure <70 mmHg. The cell
isolation protocols have been published previously.2,31 Patients char-
acteristics are listed in Table S1.
Cell Culture
APCs were cultured on ﬁbronectin and gelatin in endothelial cell
growth medium-2 (EGM-2) with all growth factors and 2% fetal
bovine serum (FBS) (Lonza) as previously described.2,16 The antigenic
proﬁle for APCs was determined by ﬂuorescence-activated cell sort-
ing (FACS) and immunocytochemistry, as previously described.4 In
brief, cells were ﬁxed with freshly prepared 4% paraformaldehyde
(PFA) and probed with the following antibodies: PDGFR-b,
VE-cadherin (1:50, Santa Cruz), GATA-4 (1:100), and vimentin
(1:400, Abcam) followed by Alexa Fluor 488 anti-rabbit or anti-
mouse secondary antibodies (Invitrogen). Isotype negative controls
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nuclei were stained with 300 nM DAPI (Thermo Fisher Scientiﬁc).
Images were acquired with a ﬂuorescent microscope (Olympus
BX40) at 40 magniﬁcation and merged using ImageJ software. All
experiments were performed at passage 7 (P7). To induce hypoxia,
APCs were incubated in 2% oxygen (multi-gas incubator, MC0-
19M-PE, Panasonic) for the time points described. Conditioned
media, protein, and RNA were then collected for further study.
HUVECs (Lonza) were grown in EGM-2 with all growth factors
and 2% fetal calf serum (FCS). The phenotypical characterization
of MCPs was carried out by immunoﬂuorescence staining for the
typical PC markers NG2, CD146, and PDGFR-b, the muscle marker
CD56 and the endothelial (CD31) and satellite cell (PAX7) markers.
Moreover, MPC identity was assessed by ﬂow cytometry analysis of
MPCs using anti-ALP antibody (from BD Biosciences). Fluorescence
was analyzed in a FACSCanto ﬂow cytometer using the FACSDiva
software (BD Biosciences) setting a non-labeled population as nega-
tive control.31
miRNA Array
Four independent APC lines were exposed to normoxic (20%) or hyp-
oxic (2%) O2 conditions for 48 hr in serum-free EGM-2. Total RNA
was extracted as described below. RNA samples were sent to Exiqon
to perform a miRCURY LNA Universal RT miR PCR panel. miRNA
array ampliﬁcation was performed on a Roche Lightcycler 480.
Cell Transfection
Opti-MEM media (Thermo Fisher Scientiﬁc) and Lipofectamine
2000 (Invitrogen) was used to transfect APCs with hsa-miR-532-
5p miRVana miRNA mimic (MC11553) (ﬁnal concentration
1 nM), hsa-miR-532-5p anti-miR miRNA inhibitor (AM11553)
(both Applied Biosystems), or on-target plus BACH1 SMARTpool
siRNA (L-007750-00-0005, GE Healthcare) (all ﬁnal concentration
25 nM). miRVana miRNA mimic negative control #1 (4464058),
anti-miR miRNA inhibitor negative control #1 (AM17010) (Applied
Biosystems), and Silencer Select Negative Control No. 2 siRNA,
(Thermo Fisher Scientiﬁc) were used as controls (ﬁnal concen-
tration 25 nM). Overexpression or silencing was conﬁrmed by




APCs were cultured under normoxic or hypoxic conditions for 48 hr
in EGM-2 without FCS. A further plate of cells was subjected to hyp-
oxia for 48 hr in EGM-2 without FCS, followed by 48 hr in normoxia
with EGM-2 containing FCS to replicate an in vivo ischemia-reperfu-
sion injury. RNA and conditioned media (CM) were collected.
Functional Assays
Cell apoptosis (caspase 3/7, Promega), metabolism (MTS assay,
Promega), viability (viability/cytotoxicity assay, Biotium), and prolif-
eration (EdU, Thermo Fisher Scientiﬁc) were performed in triplicate
according to manufacturer’s instructions.Scratch Assay
Migration was measured on gelatin and ﬁbronectin-coated multi-well
plates and manual scratch distance was measured after 18 and 24 hr,
as described previously.2 Percentage of gap closure (%GAP) was
calculated as following: %GAP = 100  (100*D1/D0).
Endothelial Resistance
The effects of miR-532-5p modulated APC-conditioned media on
HUVEC barrier properties was assessed by real-time measurement
of transendothelial resistance using an automated ECIS system
(ECIS 1600R, Applied Biophysics, NY, USA) as described previ-
ously.53,54 In brief, HUVECs were seeded into 8-well arrays (10E+,
Applied Biophysics) at a density to allow monolayer conﬂuence. Ar-
rays were attached to array holders and allowed to stabilize for 1 hr.
Resistance was then measured from each well, every 15 s for 10 min.
Media was then removed and replaced with APC-conditioned media.
Resistance measurements were made every 15 s for 1 hr.
ELISA
Anti-miR- or mimic-treated APC were incubated following transfec-
tion with 1 mL of EGM-2 without FBS or VEGF for 48 hr. Condi-
tioned media was collected and secreted Ang-1 levels were analyzed
using the manufacturer’s ELISA protocol (Bio-Techne).
In Vitro Angiogenesis
Promotion of in vitro angiogenesis by APCs was assessed using a Ma-
trigel assay (BD Biosciences). HUVECs (Lonza) and APCs were
cultured together in a 96-well plate on 70 mL Matrigel in a ratio of
3:1 HUVEC:APC for 6 hr. Total tube length was measured, along
with the number of APCs found on nodes and branches. To visualize
APCs, the cells were stained with long-term cell tracker VyBrant diI
(Life Technologies, UK). DiI was diluted 1:1,000 in PBS and incu-
bated with adherent conﬂuent APCs for 5 min at 37C and then on
ice for a further 15 min in the dark. Cells were then washed with
PBS, left to recover for 24 hr, then used for experiments.
To determine the role of Ang-1 in HUVEC network formation,
HUVECs were cultured on Matrigel with PC-conditioned media
plus a Tie-2 inhibitor (Abcam). In brief, HUVECs in 100 mL
EGM-2 were seeded onto 70 mL Matrigel along with either 100 mL
serum-free-conditioned media from PCs treated with scrambled
sequence or miR-532-5p mimic plus/minus 7.5 mM Tie-2 inhibitor.
Cells were incubated for 6 hr, then the total tube length measured.
RNA Extraction and Quantitative Real-Time Analysis
Total RNA was extracted using miRNeasy kit (QIAGEN). RNA
concentration and purity were assessed using a NanoDrop 2000
Spectrophotometer (Thermo Fisher Scientiﬁc). A miR Reverse Tran-
scription Kit (Applied Biosystems) along with speciﬁc miRNA assay
probe hsa-miR-532-5p (cat no. 001518) were used to determine
miRNA expression. miRNA expression was normalized to U6 (cat
no.001973) (Applied Biosystems). For mRNA analysis, RNA was
reverse transcribed using a High Capacity RNA-to-cDNA Kit
(Applied Biosystems). cDNA ampliﬁcation was performed on aMolecular Therapy Vol. 26 No 12 December 2018 11
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UBC (Hs00824723_m1). Expression of ANG-1 (Hs00375822_m1),
BACH1 (Hs00230917_m1), VEGFA (hs00900055_m1), HIF1AN
(hs00215495_m1), EGLN1 (Hs00254392_m1), RUNX3 (Hs00231709_
m1), TRAPPC2P1 (Hs00249201_m1), METTL20 (Hs00697698_m1),
ZFHX3 (Hs00199344_m1), and CPNE1 (Hs00537765_m1) (all
Applied Biosystems) was measured. The mRNA expression level was
determined using the 2Dct method. Each reaction was performed in
triplicate.
Luciferase Assay
To investigate whether miR-532-5p directly regulates BACH1 expres-
sion, portions of the 30 UTR of the potential target gene was inserted
downstream of a luciferase open reading frame (pLUC). BACH1 30
UTR vector was purchased from SwitchGear Genomics. Vectors in
which ﬁve nucleotide mutations were inserted in the 30 UTR se-
quences (position 2,982–2,988 of BACH1 30 UTR) complementary
to the miR-532 “seed” sequence were prepared using GeneTailor kit
(Invitrogen). Primers are as follows: forward, 50-TTTAAATGTTT
TATTttaattaGTAATAAACTAT-30, and reverse, 50-AATTTTCA
TTCTACCCAACAAGTTTC-30. Luciferase constructs were trans-
fected into HEK293T cells together with pRenilla vector and either
miR-532-5p mimic or a scrambled oligonucleotide sequence (con-
trol). Cells were cultured for 48 hr and assayed with the Dual-Lucif-
erase Reporter Assay System (Promega).
Protein Extraction
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer
containing phosphatase and proteinase inhibitors (1:100, both
Sigma). After incubation on ice, the whole APC lysates were centri-
fuged at 12,000  g for 10 min at 4C. Protein concentration was
quantiﬁed using a BCA protein assay (Thermo Fisher Scientiﬁc).
Western Blotting
Protein samples were prepared in Laemmli loading buffer, incubated
for 10 min at 95C, resolved on 7.5% SDS-PAGE, and transferred
onto polyvinylidene ﬂuoride (PVDF) membranes (Immobilon-P
PVDF Transfer Membrane 0.45 m, Millipore). Membranes were
blocked using 5% BSA or 5% non-fat dried milk in Tris-buffered
saline (TBS) containing 0.05% Tween 20 (Sigma-Aldrich) for 1 hr
at 15C–25C. Primary antibodies for BACH1 (1:200, clone F9, Santa
Cruz) and actin (loading control, 1:5,000, Clone AC15, Sigma-Al-
drich), along with anti-mouse immunoglobulin G (IgG) secondary
antibody (1:5,000, GE Healthcare, Thermo Fisher Scientiﬁc) were uti-
lized. Membrane development was performed by an enhanced chem-
iluminescence-based detection method (ECL PrimeWestern Blotting
Detection Reagent, GE Healthcare, Thermo Fisher Scientiﬁc) using a
ChemiDoc MP system (Bio-Rad). Blot densitometry was analyzed by
using the ImageJ 5.1 software.
ChIP Assay
Nuclei were isolated from formaldehyde (1% ﬁnal)-ﬁxed APCs by
lysing in ChIP Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris-
HCL [pH 8.1]) supplemented with protease inhibitors. Chromatin12 Molecular Therapy Vol. 26 No 12 December 2018was fragmented by sonication (13 cycles, 60”ON/30”OFF) using a
Bioruptor UCD-300 ultrasound sonicator (Diagenode), resulting in
300- to 500-bp DNA fragments visualized on 1% agarose gel. Chro-
matin was diluted in dilution buffer (1% Triton X-100, 2 mM
EDTA [pH 8.0], 150 mM NaCL, 20 mM Tris-HCl [pH 8.1] supple-
mented with protease inhibitors). DNA-cross-linked proteins were
immunoprecipitated in 1-mL reaction (1% kept as input) using
5 mg of BACH1 (sc-271211 X, Santa Cruz) or control mouse IgG anti-
body. The antibody was pulled down with protein G beads (Dyna-
beads 10003D, Invitrogen) at 4C overnight. The beads were sepa-
rated with a magnetic rack and washed sequentially for 3 min with
1 mL of the following buffers: 3 low-salt wash buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl
[pH 8.1]), 2 high-salt wash buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl [pH 8.1]), 1 LiCl
wash buffer (0.25 M LiCl, 1% nonidet P-40, 1% sodium deoxycholate,
1 mM EDTA, 10 mM Tris-HCl [pH 8.1]) and 2 Tris EDTA (TE)
buffer (10 mM TrisHCl [pH 8.0], 1 mM EDTA). A 10% proportion
from the ﬁnal wash was retrieved, and samples prepared for running
on western blot (as described above) to assess the immunoprecipita-
tion (IP) for BACH1 size. Antibody-chromatin complexes were
eluted in 200 mL of elution buffer (100 mM NaHCO3, 1% SDS,
5 mM NaCl) with vigorous shaking overnight at 65C. Proteins
were digested from the eluate by adding 2 mL of proteinase K
(10 mg/mL, Sigma) and incubating for further 2 hr at 65C. Associ-
ated DNA was then puriﬁed by extraction using Monarch PCR &
DNA Cleanup Kit (T1030S, New England Biolabs). Immunoprecipi-
tated DNA and total input were used as a template for real-time
qPCR. The ChIP primers for ampliﬁcation of region 1 and region 2
are as follows: primer region 1, Fw 50-CCT TTG GGG CCA TAA
GAT TT-30, Rev 50-CCG GTC ACA ATC TTT CCA CT-30; primer
region 2, Fw 50-GCA TGA TTT AAG CCC AGC AG-30, Rev
50-CTG GAT TCT TTG AGG GAA CG-30. ChIP was performed
in duplicate using 1  107 APCs per sample, and qPCR repeated
three times in triplicate. The NEUROD1 promoter region
(chr5:134,872,623–134,877,626) was used as a negative control for
the absence of BACH1 binding to the promoter, and heme oxygen-
ase-1 (HMOX1 promoter region chr22:35,767,428–35,777,046) used
as a positive control.
Animal Experiments
Experiments were performed in accordance with the Animal (Scien-
tiﬁc Procedures) Act (UK) 1986 prepared by the Institute of Labora-
tory Animal Resources and under the auspices of UK Home Ofﬁce
Project (60/4523) and Personal License (70/25771). Results are re-
ported following the guidelines contained in the Animal Research
Report of In Vivo Experiments (ARRIVE).
Induction of Diabetes and Limb Ischemia
Six- to seven-week-old-male CD-1 mice were made diabetic using
STZ (Sigma) or left normoglycemic after STZ buffer administration
alone. STZ was delivered intraperitoneally (i.p.) for 5 consecutive
days (40 mg kg1 in citrate buffer per day). Fourteen days after
the ﬁrst STZ injection, glycemia after fasting and glycosuria were
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overt glycosuria entered the protocol. The absence of hyperglycemia
and glycosuria in buffer-injected non-diabetic mice was also veriﬁed.
Three months after the onset of hyperglycemia, unilateral hindlimb
ischemia was surgically induced in anesthetized mice (tribromoetha-
nol, 880 mmol/kg i.p., Sigma) using a reﬁned procedure that consists
of ligation (with a 7-0 silk suture) in two points and electrocoagula-
tion of the upper part of the left femoral artery but leaving the femoral
vein and nerve untouched. The superﬁcial blood ﬂow of the ischemic
and contralateral feet was sequentially analyzed (at 30 min, 3, 7, and
15 days) by color laser Doppler (Moor, USA), and the ratio of blood
ﬂow between the ischemic foot and the contralateral foot was calcu-
lated and used as an index of % blood ﬂow recovery.
For analysis of vascularization, muscular sections were stained as pre-
viously described.55 In brief, muscles were excised and whole-mount
preparation was performed by ﬁxing in 2% PFA and then embedded
in optimal cutting temperature (OCT). Sections were incubated over-
night at 4Cwith Alexa 488-conjugated isolectin B4 (1:100; Life Tech-
nologies) to identify ECs. Slides were observed under a ﬂuorescence
microscope (Olympus BX40). The number of capillaries per ﬁeld
was counted, and capillary density was expressed as the number of
vessels per mm2 of muscular sections.
Isolation of NG2-Positive PCs from Mouse Limb Muscles
At 0, 3, 7, and 15 days post-ischemia, adductor muscles were rinsed
and digested with collagenase II (Worthington) plus DNase I (Sigma)
using gentleMACS Dissociator, following the manufacturer’s proto-
col. Next, PCs were immunomagnetic sorted using NG2 antibodies
(Miltenyi Biotech), as reported.15 The purity of cell preparations
was analyzed by ﬂow cytometry using NG2-PE (eBioscience, 8012-
6504-120, 1:50) antibodies. Expression of miR-532-5p by these cells
was then determined by qPCR as described above.
Matrigel Plug Assay
To determine the effect of miR-532-5p expression on APCs’ ability to
colonize endothelial networks, cold Matrigel was mixed with GFP-
labeled APCs (infected with lentiviral vector pLKO-Puro-CMV-
GFP at 10 MOI) and transfected with anti-miR, mimic, or respective
scrambled sequences (as control). Eight-week-old male CD1 nude
mice (Crl:CD1-Foxn1nu; Charles River) were injected subcutane-
ously into both abdominal ﬂanks with 500 mL growth factor-reduced
Matrigel (BD Bioscience) supplemented with ﬁbroblast growth factor
(FGF)2 (250 ng/mL; R&D Systems), under anesthesia induced by iso-
ﬂurane inhalation. Twenty-one days later, the animals were sacriﬁced
and the Matrigel plugs were harvested, ﬁxed in 4% paraformaldehyde
at 4C overnight, and embedded in OCT. Implant sections of 4-mm
thickness were incubated overnight at 4C with the speciﬁc endothe-
lial marker VE-cadherin (Santa Cruz), while anti-GPF (Invitrogen)
antibody was used to visualize PCs. Sections were then incubated
with Alexa 488-conjugated goat anti-rat and anti-rabbit IgG second-
ary antibodies, respectively (Invitrogen). Nuclei were counterstained
with DAPI. Mounted sections were imaged with 20, 40, or 100objective by Zeiss LSM780 confocal microscope. Microvessel density
was quantiﬁed in 30 ﬁelds covering the whole cross-section of theMa-
trigel plug. The VE-cadherin-positive neovessel area covered with
PCs inside implants was quantiﬁed using ImageJ software version
7.7.2.
In Silico Analysis
Computational prediction of miR-532-5p target genes was performed
using published algorithm TargetScan 7.1.56 Analysis of regulatory
elements onANG-1 promoter was performed using GeneHancer soft-
ware.57 Super-enhancer genomic location chr8:6,424,533–6,430,579
and chr8:6,744,218–6,751,460.
Statistical Analysis
All data were analyzed using GraphPad Prism software (v6). Compar-
ison of multiple groups was performed by analysis of variance
(ANOVA) and Bonferroni post-test multiple comparison tests. A
two-group analysis was performed by Student’s t test. Values were ex-
pressed as means ± SE. p values less than 0.05 were considered
signiﬁcant.
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